Evidence map›Paper›PMID 34439748›Full record

ArticleBiomolecules2021

Specification and Evaluation of Plasticizer Migration Simulants for Human Blood Products: A Delphi Study.

Aurélie Thelliez, Grégory Hénard, Bruno Delorme, Sonia Chatellier, Cécile Danel, Laurent Ducoroy, Annabelle Dupont, Delphine Garrigue, Stéphanie Genay, Jean-François Goossens and 11 more

Abstract read
In one paragraph

Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Aurélie ThelliezUniv. Lille, CHU Lille, ULR 7365 GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.
Grégory HénardMacopharma, 200 Chaussée Fernand Forest, F-59200 Tourcoing, France.
Bruno DelormeMacopharma, 200 Chaussée Fernand Forest, F-59200 Tourcoing, France.
Sonia ChatellierKREADYS, 7000 Mons, Belgium.
Cécile DanelUniv. Lille, CHU Lille, ULR 7365 GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.
Laurent DucoroyMacopharma, 200 Chaussée Fernand Forest, F-59200 Tourcoing, France.
Annabelle DupontCHU Lille, Service D'hémostase et Transfusion, Centre de Biologie Pathologie, F-59037 Lille, France.
Delphine GarrigueCHU Lille, Department of Anesthesiology and Critical Care, F-59000 Lille, France.
Stéphanie GenayUniv. Lille, CHU Lille, ULR 7365 GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.
Jean-François GoossensUniv. Lille, CHU Lille, ULR 7365 GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.
Laurence GoossensUniv. Lille, CHU Lille, ULR 7365 GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.
Coralie HavetMacopharma, 200 Chaussée Fernand Forest, F-59200 Tourcoing, France.
Jean-Daniel HecqCHU UCL, Drug Stability Research Group, Namur, 5530 Yvoir, Belgium.ORCID 0000-0002-7223-8259
Caroline MaeghtMacopharma, 200 Chaussée Fernand Forest, F-59200 Tourcoing, France.
Isabelle MendelCHU Lille, Institut D'hémato-Transfusion, Unité D'hémovigilance, F-59000 Lille, France.
Tomé NajdovskiService du Sang, Croix-Rouge de Belgique, rue du Fond de Maréchal, 8/1, 5020 Suarlée, Belgium.
Pascal OdouUniv. Lille, CHU Lille, ULR 7365 GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.
Guillaume Saint-LorantUniversité de Caen Normandie, Unirouen, ABTE, F-14000 Caen, France.
Alexandre UngCHU Lille, Service D'hémostase et Transfusion, Centre de Biologie Pathologie, F-59037 Lille, France.
Marie LecoeurUniv. Lille, CHU Lille, ULR 7365 GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.
Bertrand DécaudinUniv. Lille, CHU Lille, ULR 7365 GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.ORCID 0000-0001-8267-5594

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Potentially toxic plasticizers are commonly added to polyvinyl chloride medical devices for transfusion in order to improve their flexibility and workability. As the plasticizers are not chemically bonded to the PVC, they can be released into labile blood products (LBPs) during storage. Ideally, LBPs would be used in laboratory studies of plasticizer migration from the medical device. However, short supply (i.e., limited stocks of human blood in collection centres) has prompted the development of specific simulants for each type of LBP in the evaluation of new transfusion devices. We performed a Delphi study with a multidisciplinary panel of 24 experts. In the first (qualitative) phase, the panel developed consensus definitions of the specification criteria to be met by each migration simulant. Next, we reviewed the literature on techniques for simulating the migration of plasticizers into LBPs. A questionnaire was elaborated and sent out to the experts, and the replies were synthesized in order to obtain a consensus. The qualitative study established specifications for each biological matrix (whole blood, red blood cell concentrate, plasma, and platelet concentrate) and defined the criteria required for a suitable LBP simulant. Ten criteria were suggested: physical and chemical characteristics, opacity, form, stability, composition, ability to mimic a particular clinical situation, ease and safety of use, a simulant-plastic interaction correlated with blood, and compatibility with analytical methods. The questionnaire data revealed a consensus on the use of natural products (such as pig's blood) to mimic the four LBPs. Opinions diverged with regard to synthetic products. However, an isotonic solution and a rheological property modifier were considered to be of value in the design of synthetic simulants. Consensus reached by the Delphi group could be used as a database for the development of simulants used to assess the migration of plasticizers from PVC bags into LBPs.

Indexed as

Blood BanksBlood CellsBlood PlateletsBlood PreservationBlood TransfusionDelphi TechniqueErythrocytesHematologyHumansHydrogen-Ion ConcentrationInterdisciplinary CommunicationMaterials TestingPlasmaPlasticizersPolyvinyl ChlorideSurface PropertiesPlasticizersPolyvinyl Chloridelabile blood productmigrationplasticizersimulant

Identifiers

PMID34439748
PMCPMC8392596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.